Proph wrote: - As we wait for the "fulsome" update from CSCI "shortly", in the words of the last news release nine days ago, and the imminent top-line results from the pediatric diagnostic trial, initiation of the multi-dose phase of the avenanthramide clinical trial as well as first potential human trial results, and the potential peer-review article on PGX-YBG/fibrosis, as well as the PGX presentation on October 8, 2024 before a conference of engineers I wondered about the potential for analyst coverage. AEZS had coverage from H.C. Wainwright before the merger so analyst coverage wouldn't be unprecedented for AEZS. Given Bloom Burton and Research Capital participated in the merger what is the likelihood they will initiate coverage assuming the expected events are positive. I asked Perplexity Ai and this was the response:
Well proph we have been waiting for years and everytime we are promised something (usually before a vote) nothing happens, that is gagnon's legacy, lies (just ask Oats) failures after failure (montreal heart institute) and failed companies. Everything gagnon has had control of he has failed and driven into the ground while collecting millions. Ceapro, Juvenite and Aezs all gagnon failures Those are the facts and probably why Wainwright nolonger covers gagnon led comany. Hell he can't even produce PGX on a mini commercial scale, another faulre, nine months past due on the promise and nothing. Oh but wait till Oct, another delay and failure and nothing will be done.
gagnon's track record is proven just ask any shareholder of the previous 3 companies he run into the ground (SOON TO BE 4) about gagnon's word. JUST A BIG FAILURE and his promises and word mean ABSOLUTELY NOTHING